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Pseudomyxoma peritonei (PMP) and extragastrointestinal stromal tumors (E-GISTs) are both rare entities. Most of the time, PMP
is associated with an appendiceal tumor. An ovarian mucinous tumor can mimic appendiceal metastases. E-GIST is a mesen-
chymal tumor that can arise from the omentum, retroperitoneum, mesentery, or pleura. We present a case of an 87-year-old
woman with mucinous carcinomatosis and acute intestinal occlusion submitted to an emergency laparotomy. She has found to
have a borderline mucinous tumor of the ovary from the intestinal type with several lesions of pseudomyxoma peritonei and an
E-GIST from the epiploons retrocavity (intermediated risk). In the literature, no relation was found between these two rare
tumors. E-GIST was an incidental ﬁnding in the context of a mucinous carcinomatosis.
1. Introduction
Mucinous carcinomatosis or pseudomyxoma peritonei
(PMP) is an accumulation ofmucinous ﬂuid in the abdominal
cavity. Most cases are caused by mucin-producing tumors of
the appendix and ovary [1]. Mucinous tumors represent 32%
of all epithelial borderline ovarian tumors, the intestinal type
being the most common (90%) [2]. Gastrointestinal stromal
tumors (GISTs) account for only 2% of all gastrointestinal
neoplasms and are the most common mesenchymal tumor of
gastrointestinal type [3]. More than 95% of GISTs express the
KIT protein (CD117). Extragastrointestinal stromal tumor
(E-GIST) develops outside the gastrointestinal (GI) tract, such
as the omentum, mesentery, and retroperitoneum [4]. +e
incidence of E-GIST is estimated to be 10% of all GISTs, but
the pathologic characteristics and clinical outcomes are still
on debate due to its rarity [5].
2. Case Report
We present the case of an 87-year-old woman with a rela-
tively good performance status brought to the emergency
room with progressive asthenia, weight loss, and abdominal
distension for the last two months. She had a previous di-
agnosis of diabetes mellitus under oral antidiabetics and
hypercholesterolemia and no previous surgical procedures.
On physical examination, she was pale, emaciated, afebrile,
and with abdominal distension for ascites without tension.
Edema in the lower members was also present.
On laboratory workup, a minor microcytic anaemia was
detected; renal function, liver markers of cytolysis, and
inﬂammatorymarkers were normal. Tumormarkers, such as
carcinoembryonic antigen and carbohydrate antigen 19.9
and 125, were within normal range. She was admitted for
further workup.
Abdominal ultrasound described a mass between the
stomach and pancreas with about 9 cm and large volume
ascites. Abdominal CT scan described a lobulated mass
anterior to the pancreas with 8.5× 9.5 cm, signs of chronic
liver disease, and conﬁrmed large volume ascites (Figure 1).
Endoscopic study of both high and low GI tract was normal.
A paracentesis revealed a mucinous content, negative in
microbiologic cultures. Cytology and biochemical analysis
were inconclusive.
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One week after admission, the patient had persistent
vomiting and dyspnea caused by increased abdominal dis-
tension. An emergency laparotomy was performed. A total
of 12 L of mucinous ascites (Figure 2) was removed, and two
lesions were identiﬁed. +e ﬁrst lesion was a multiloculated
mass in the left ovary (Figure 3), and the second was
a lobulated mass in the epiploons retrocavity near the
pancreas (Figure 4). Both tumors were totally removed. No
macroscopic changes were found in the appendix. Pathology
revealed brownish membranous areas and multiple cystic
formations with gelatinous and yellowish content suggestive
of borderline mucinous tumor of the ovary of the intestinal
type with broken capsule and several lesions of pseudo-
myxoma peritonei (pT1c Nx (FIGO IC)) (Figure 5) [6, 7]. An
appendiceal origin or a teratomatous component was ex-
cluded.+e second tumor was an E-GISTfrom the epiploons
retrocavity, with a low mitotic index (2/50 HPF). Immu-
nohistochemically, the tumor cells were positive for CD34,
DOG1, and CD117 but negative for S100 protein (Figure 6).
+e patient had full recovery from surgery without any
complications. After a multidisciplinary discussion, no ad-
juvant therapy was performed, and the patient was dis-
charged to a palliate care facility. Within the two years of
Figure 1: CT scan showing a lobulated mass in front of the
pancreas measuring 8.5× 9.5 cm (arrow), signs of chronic liver
disease, and high-volume ascites.
Figure 2: High volume of mucinous ascites.
Figure 3: A multiloculated mass in the left ovary.
Figure 4: A lobulated mass in the epiploons retrocavity near the
pancreas.
Figure 5: Borderline mucinous tumor of the ovary (intestinal type;
HE 20x).
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follow-up, the patient did not present any evidence of
recurrence.
3. Discussion
Pseudomyxoma peritonei is a clinical condition more fre-
quently originated in a perforated mucinous tumor of the
appendix. +e accumulation of gross mucinous ascites can
lead to adhesions and cause intestinal obstruction.
+e clinical course is insidious, and multiple recurrences
are common. Surgery with cytoreductive therapy and in-
traperitoneal chemotherapy is the approach with better
outcomes described.
A primary ovarian tumor rarely causes PMP and the
most frequently associated subtype is the mature teratoma
[8, 9]. It is important to diﬀerentiate a primary tumor from
those arising from the appendix and amucinous tumor from
the ovary since they can share some histological aspects
[10, 11].
Some available data suggested that “borderline” mu-
cinous tumor from the ovary can be originated from
a primary appendiceal lesion. When the lesion presents
benign and borderline areas and smooth surface and is
unilateral and limited to the ovary, these characteristics
point to ovarian origin. Pathologists use a panel of im-
munohistochemical markers for ovarian origin (CK7,
CK20, and CDX-2) even though some combinations can be
shared with other tumors (pancreatobiliary, upper gas-
trointestinal tract, lung, and breast). Metastatic lesions are
more common and usually present as small diﬀuse lesions
with an inﬁltrative pattern of stromal invasion [12].
In the case presented above, the appendix was not
resected because it did not show abnormal appearance and
a unilateral lesion in the ovary was resected.
+e other tumor removed was characterized as an
E-GIST, a mesenchymal tumor that originates from in-
terstitial cells of Cajal and arises outside the GI tract. While
some authors consider that E-GISTs may originate as pri-
mary tumors from mesenchymal stem cells of the greater
omentum and mesentery, others consider that these tumors
derive from the gastrointestinal tract like the other GISTs
and may represent a metastatic stage [13].
+e tumor could be asymptomatic for a months or years
and sometimes can be palpable.+e presence of symptoms is
associated with a large lesion. Most of cases are diagnosed
through CT scan. +e lesions are usually single, well
delimited, and with low density [3].
Yi et al. [14] published a revision of 51 patients with
E-GIST in South Korea. +e most common location was the
mesentery (n� 15) followed by the retroperitoneum (n� 13)
and omentum (n� 8).
Several case series studied grading systems for these
tumors. Usually, tumor size and mitotic rate are used to
classify the other GISTs. As we discussed above, E-GISTs are
more frequently symptomatic only when they are already
large masses. +erefore, size is not probably as useful for
grading as for the other GISTs. Mitotic rate, cellularity, and
Ki67 expression seem to be the most signiﬁcant prognostic
factors. In most cases, E-GISTs are large tumors associated
with high proliferative rates, sometimes with lymph node
and distant metastasis, which entails a worse prognosis
[15, 16].
Yamamoto et al. [5] deﬁned three categories: the high-
risk group (≥5/50 HPF with ≥10% Ki67), the intermediate-
risk group (≥5/50HPF with <10% Ki67 or <5/50 HPF with≥10% Ki67), and the low-risk group (<5/50 HPF with <10%
Ki67). +is classiﬁcation can be useful to determine the
indication for adjuvant therapy.
Surgical resection is the treatment of choice. After the
surgery, patients are selected for treatment with inhibitors of
tyrosine kinase that follows the NIH criteria: tumor size,
mitotic rate, and anatomic location. Our patient’s tumor was
classiﬁed as moderate risk, and no adjuvant treatment was
given.
No relationship between a borderline ovarian mucinous
tumor and an E-GISTwas found in the literature [17, 18]. In
the same way, pseudomyxoma peritonei was not related with
any type of GIST. From our point of view, these two tumors
presented as synchronous and unrelated. Looking for the
characteristics of the E-GIST, this tumor probably developed
for a long time before and was an incidental ﬁnding in the
context of a mucinous ascites from another primary tumor.
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